Nebenwirkungen · Kineret
Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe. · Abschnitt 4.8 · PDF-Seite 8
HOS-108747 · Präparat HOS-093075
Summary of the safety profile In placebo-controlled studies in RA patients, the most frequently reported adverse reactions with Kineret were injection site reactions (ISRs), which were mild to moderate in the majority of patients. The most common reason for withdrawal from study in Kineret-treated RA patients was injection site reaction. The subject incidence of serious adverse reactions in RA studies at the recommended dose of Kineret (100 mg/day) was comparable with placebo (7.1% compared with 6.5% in the placebo group). The incidence of serious infection was higher in Kineret-treated patients compared to patients receiving placebo (1.8% vs. 0.7%). Neutrophil decreases occurred more frequently in patients receiving Kineret compared with placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-15T12:46:00Z · SHA-256 53a0a98f576dc350e42d4cc85e11cf9eeb4b97cf7707add713e0c1a596152e85 · Passage 3917cf968f1b540fec49564b9fd029f1b723c2f082b0d93283c37b89e62290dd · Zeichen 0–757 im Abschnitt